Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behçet's disease.
Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behçet's disease.
复制标题
糖蛋白 2 抗体在区分 CD 与肠结核和肠白塞氏病方面比 ASCA 具有诊断优势
DOI：
10.1038/ctg.2018.1
复制
发表时间：
2018-02-15
影响因子：
3.6
通讯作者：
Li Y
中科院分区：
文献类型：
--
作者：
Zhang S;Luo J;Wu Z;Roggenbuck D;Schierack P;Reinhold D;Li J;Zeng X;Zhang F;Qian J;Li Y
越来越需要鉴定可靠的生物标志物来区分克罗恩病（CD）与具有相似临床和病理特征的其他胃肠道疾病。本研究旨在评价酶原颗粒糖蛋白GP 2（aGP 2）抗体在一个大型、明确的中国队列中的诊断潜力，特别关注其在区分CD与肠白塞病（BD）和肠结核病（ITB）中的作用。共前瞻性入组了577例受试者，其中包括171例CD患者、208例溃疡性结肠炎（UC）患者、71例BD患者、57例ITB患者和70例健康对照（HC）。通过ELISA测定aGP 2和抗酿酒酵母抗体（ASCA）。间接免疫荧光法检测核周抗神经细胞胞浆抗体。CD患者的aGP 2 IgG和伊加水平显著高于UC、肠BD、ITB和HC患者。相反，CD和肠BD患者之间的ASCA IgG水平没有差异，而ASCA伊加水平不能区分CD与肠BD和ITB患者。aGP 2伊加和IgG在区分CD与疾病对照方面显示出比ASCA伊加和IgG更好的测定性能（更大的曲线下面积）（P<0.05）。ASCA伊加没有区分CD和疾病对照。aGP 2伊加和/或IgG与穿透性疾病（B3）和回肠CD（L1）显著相关（P<0.05），而ASCA伊加和/或IgG与穿透性疾病（B3）和回肠CD（L1）无关。与ASCA相比，aGP 2更有效地将CD与肠道BD或ITB区分开来，作为疾病对照，有助于IBD的鉴别诊断。
There is an increasing need to identify reliable biomarkers for distinguishing Crohn’s disease (CD) from other gastrointestinal disorders sharing similar clinical and pathological features. This study aimed at evaluating the diagnostic potential of antibodies to zymogen granule glycoprotein GP2 (aGP2) in a large, well-defined Chinese cohort with a special focus on their role in discriminating CD from intestinal Behçet's disease (BD) and intestinal tubercolosis (ITB). A total of 577 subjects were prospectively enrolled, including 171 patients with CD, 208 patients with ulcerative colitis (UC), 71 with BD, 57 with ITB and 70 healthy controls (HC). aGP2 and anti-Saccharomyces cerevisiae antibodies (ASCA) were determined by ELISA. Perinuclear antineutrophil cytoplasmic antibodies were tested by indirect immunofluorescent assay. aGP2 IgG and IgA levels were significantly elevated in patients with CD compared with those in patients with UC, intestinal BD, and ITB and HC. Conversely, ASCA IgG levels were not different between CD and intestinal BD patients, whereas ASCA IgA levels did not discriminate CD from intestinal BD and ITB patients. aGP2 IgA and IgG displayed a better assay performance (larger areas under the curve) over ASCA IgA and IgG in differentiating CD from disease controls (P<0.05). ASCA IgA did not discriminate CD from disease controls. aGP2 IgA and/or IgG was significantly associated with penetrating disease (B3) and ileal CD (L1) (P<0.05), whereas ASCA IgA and/or IgG was not. In comparison with ASCA, aGP2 distinguishes CD from intestinal BD or ITB as disease controls more efficiently, aiding in the differential diagnosis of IBD.
登录
查看更多内容
影响因子：
9.8
作者：
Lawrance, IC;Murray, K;Leong, R
通讯作者：
Leong, R
影响因子：
3.1
作者：
Makharia, Govind K.;Sachdev, Vikas;Pandey, R. M.
通讯作者：
Pandey, R. M.
影响因子：
4.3
作者：
Prideaux, Lani;Kamm, Michael A.;Dotan, Iris
通讯作者：
Dotan, Iris
影响因子：
4.9
作者：
Michaels, Maike Anna;Jendrek, Sebastian Torben;Sina, Christian
通讯作者：
Sina, Christian
影响因子：
24.5
作者：
Roggenbuck, D.;Hausdorf, G.;Conrad, K.
通讯作者：
Conrad, K.